A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

Health experts are raising concerns for women using popular weight loss medications, particularly GLP-1s like Wegovy, ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.